In-vitro product performance of fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) delivered from a dry powder inhaler (DPI) using the Electronic Lung (EL) to replicate patient inhalation profiles

This abstract will be presented at ERS 2019 in Madrid, Spain.

Thorsten Aldekamp is presenting this Encore on behalf of all authors with their permissions.

Introduction: When using a DPI, critical patient inhalation characteristics such as inspiratory flow rate and inhaled volume vary widely between individuals, disease state and severity.

Aim: This study aimed to evaluate the dose delivery performance of a triple combination DPI (Trelegy ELLIPTA) containing FF/UMEC/VI 100/62.5/25 µg, across the full range of inhalation characteristics relevant to patients with all severities of chronic obstructive pulmonary disease (COPD).

Method: Five representative pre-recorded patient inhalation profiles encompassing the full range of peak inspiratory flow rates (PIFRs) for patients of all COPD severities (Prime D, et al. J Aerosol Med Pulm Drug Deliv, 2015), were replicated using the EL breathing simulator with a coated anatomical throat model and Next Generation Impactor (Hamilton M, et al. J Aerosol Med Pulm Drug Deliv, 2015). Dose deposited within the throat and impactor stages were analysed to determine the delivered dose (DD) and fine particle dose (FPD, mass < 5 µm).

Results: Mean DD and FPD were consistent for FF, UMEC and VI ([Fig. 1]) across the full range of patient-relevant inhalation characteristics, including PIFR 43.5 to 129.9 L/min.

Fig. 1 

Conclusion: COPD patients, including those with very severe COPD, can achieve the inspiratory effort required for consistent dose delivery.

Conflicts of interest: DP, MH, ET are employees of, and hold shares in GlaxoSmithKline plc.

Funding: This study was funded by GlaxoSmithKline plc.

Trademarks are the property of their respective owners.